- Home
- AEG vs EXEL Comparison
AEG vs EXEL Comparison
Compare AEG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEG
- EXEL
- Stock Information
- Founded
- AEG 1983
- EXEL 1994
- Country
- AEG Netherlands
- EXEL United States
- Employees
- AEG N/A
- EXEL N/A
- Industry
- AEG Life Insurance
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEG Finance
- EXEL Health Care
- Exchange
- AEG Nasdaq
- EXEL Nasdaq
- Market Cap
- AEG 10.6B
- EXEL 9.7B
- IPO Year
- AEG N/A
- EXEL 2000
- Fundamental
- Price
- AEG $6.48
- EXEL $36.43
- Analyst Decision
- AEG Strong Buy
- EXEL Buy
- Analyst Count
- AEG 1
- EXEL 17
- Target Price
- AEG N/A
- EXEL $35.50
- AVG Volume (30 Days)
- AEG 5.0M
- EXEL 2.4M
- Earning Date
- AEG 02-20-2025
- EXEL 02-04-2025
- Dividend Yield
- AEG 5.39%
- EXEL N/A
- EPS Growth
- AEG N/A
- EXEL 441.02
- EPS
- AEG N/A
- EXEL 1.55
- Revenue
- AEG $13,637,629,914.00
- EXEL $2,081,598,000.00
- Revenue This Year
- AEG N/A
- EXEL $20.53
- Revenue Next Year
- AEG $1.93
- EXEL $0.95
- P/E Ratio
- AEG N/A
- EXEL $23.54
- Revenue Growth
- AEG N/A
- EXEL 17.31
- 52 Week Low
- AEG $5.53
- EXEL $20.02
- 52 Week High
- AEG $6.96
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- AEG 69.71
- EXEL 59.74
- Support Level
- AEG $5.82
- EXEL $33.05
- Resistance Level
- AEG $6.07
- EXEL $37.59
- Average True Range (ATR)
- AEG 0.08
- EXEL 1.02
- MACD
- AEG 0.07
- EXEL 0.26
- Stochastic Oscillator
- AEG 96.99
- EXEL 74.45
About AEG Aegon Ltd. New York Registry Shares
Aegon is a life insurance and long-term savings company listed in the Netherlands. It listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. Over recent years, Aegon has been moving through an extensive transformation program where management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the business that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile-earnings products and recycle funds into capital-light and more predictable strategic businesses.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.